Extended Data Fig. 13: Comparing the effects of IL-2(WT) cytokine versus IL-2(V) cytokine in PD-1 combination therapy in the LCMV chronic infection model with CD4+ T-cell help.
From: PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
a, Experimental design. Mice infected with LCMV clone 13 (day 25 post-infection) were left untreated, or treated with anti-PD-L1 antibody, anti-PD-L1 plus IL-2(WT), or anti-PD-L1 plus IL-2(V). b, Numbers of LCMV-specific DbGP33+ CD8+ T cells in the indicated tissues after the various treatments. c, Summary data for the expression of phenotypic markers on DbGP33+ or DbGP276+ CD8+ T cells in the spleen after the different treatments. d, Numbers of IFNγ+, and IFNγ+TNFα+ LCMV-specific CD8+ T cells in the four groups. Spleen cells were stimulated with pools of LCMV-specific peptides for 5 h and analysed by intracellular staining of cytokines e, Viral titre in spleen and serum in the four groups of mice. Dotted line indicates the limit of detection. Results were pooled from 3-4 experiments with 2-5 mice per group in each experiment. Data are presented as geometric mean and 95% CI (b, d) or mean and SD (c, e, f) with p values. Statistical comparisons were performed using Kruskal-Wallis test with Dunn’s multiple-comparison test (b, d, f (number of LCMV-specific CD4+ T cells)) or one-way ANOVA with Tukey’s multiple-comparison test (c, e, f (phenotype of LCMV-specific CD4+ T cells)). Untx, untreated.
